
Cantargia
1,498
SEK
-1,77 %
CANTA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
1.303 følger denne virksomhed
-1,77%
-14,35%
-11,36%
-18,05%
-61,79%
-55,58%
-89,41%
-92,39%
-78,8%
Cantargia is a pharmaceutical company. Today, there is specialization in the development of antibody drugs used in the treatment of leukemia and other cancers such as lung and pancreatic cancer. The company's objective is to develop, sell and license drug candidates to companies operating in the mentioned work area. The largest operations are in the Nordic market, with headquarters in Lund.
Læs mereMarkedsværdi
372,42 mio. SEK
Aktieomsætning
4,98 mio. SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Finanskalender
13.5
2025
Delårsrapport Q1'25
15.5
2025
Generalforsamling '25
21.8
2025
Delårsrapport Q2'25
ViserAlle indholdstyper

Cantargia publishes full year report for 2024
Cantargia to participate in Leerink Partners Global Healthcare Conference
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Invitation to presentation of Cantargia’s Year-End report 2024
Cantargia announces management changes
Cantargia announces changes in number of shares and votes
Cantargia announces outcome of the rights issue
Cantargia publishes strong preclinical effects and clinical monotherapy results on nadunolimab in pancreatic cancer in Journal for Immunotherapy of Cancer
Cantargia and GEICAM present updated phase 1 clinical data and new translational results on nadunolimab treatment in advanced triple negative breast cancer at San Antonio Breast Cancer Symposium
Cantargia publishes prospectus in connection with rights issue
Extraordinary general meeting in Cantargia AB (publ)
Cantargia expands the CAN10 phase 1 clinical program building on positive results
Redeye: Cantargia Q3 2024 - IL1RAP Companion Diagnostic Next

Cantargia, Audiocast with teleconference, Q3'24
Cantargia publishes interim report for third quarter 2024
Cantargia presents Nomination Committee ahead of 2025 AGM
Cantargia results showing efficacy of CAN10 in models of myocarditis published in Circulation: Heart Failure
